Business Context and Reporting Period
Company: ANAPTYSBIO, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2025
Reporting Period: Event date of October 14, 2025
This filing serves as a notification under Regulation FD regarding a conference call and the release of updated investor presentations focused on the company's asset, ANB033.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate communications and does not contain audited or unaudited financial statements.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing discloses the following operational updates:
- Hosting of a conference call on October 14, 2025, to discuss ANB033.
- Release of an updated corporate investor presentation.
Guidance, Outlook, and Risks
Management Commentary: The company is providing updates on its development candidate, ANB033, via a conference call and slide presentation.
Legal Disclaimer: The information contained in the exhibits (Investor Presentation and Corporate Presentation) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K filing.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Investor Presentation) and Exhibit 99.2 (Corporate Presentation) for specific data on ANB033.
- Confirm the date and time of the conference call referenced in Item 7.01.
- Note that the presentation materials are not legally "filed" under the Exchange Act and should be reviewed with the associated disclaimer in mind.